3E Bioventures Capital
3E Bioventures Capital is a venture capital firm focused on life sciences, investing in global health innovators. The firm targets Biotech, including new drugs, modalities, and drug discovery platforms, as well as TechBio, which merges biology and technology to disrupt traditional paradigms. 3E Bioventures follows a science-driven, entrepreneur-friendly investment approach, collaborating with companies and research institutions to develop solutions for unmet medical needs. The firm's philosophy is encapsulated in its name, 3E: Expertise, Efficiency, Execution.
3E Bioventures Capital
Portfolio
A first-in-class biologic drug, an AXL-Fc fusion protein which acts as a trap for Gas6 AXL signaling which plays an important role in tumor metastasis and associated EMT mechanism.
#Biotech/New Drugs
A first-in-class biologic drug targeting an important innate immunity pathway, CD24 Siglec signaling.
#Biotech/New Drugs
Pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.
#Biotech/New Drugs
Treating central nervous system disorders by targeting the cellular damage response mechanisms.
#Biotech/New Drugs
A clinical stage immuno-oncology company developing best-in-class CTLA-4 antibody and first-in-class CD24 antibody.
#Biotech/New Drugs
A first-in-class small molecule drug targeting LAT1, large amino acid transporter protein.
#Biotech/New Drugs
Next Generation 'Gene-Therapy' Drug Delivery Platform, initially targeting chronic eye diseases, expandable to other broader indications.
#Biotech/New Drugs
Utilizes revolutionary and proprietary targeted protein degradation technology to create new drugs for diseases lacking effective therapies.
#Biotech/New Drugs
Focuses on uric acid metabolism, inflammatory pain, and gout metabolic syndrome diseases.
#Biotech/New Drugs
Proprietary diverse libraries of FKBP-binding bi-functional macrocycles (rapafucins).
#Biotech/New Drugs
A private pharmaceutical company with a therapeutic focus on dermatology, founded in 2021 through a spin-off from Novaliq GmbH.
#Biotech/New Drugs
Restoring Brain Health by harnessing common disease mechanisms to create breakthrough small molecule therapeutics.
#Biotech/New Drugs
Targeting intersections for precision immunotherapy especially in antigen presentation.
#Biotech/New Drugs
A transformative new flow cytometer platform company, replacing traditional filter with optical grating, and PMT with APD.
#X-Disciplinary HealthTech
Revolutionary silicon-based platform to enable high-throughput, rapid, precise and cost-effective DNA synthesis, potentially applicable in broad fields including healthcare, industrial chemicals, agriculture.
#X-Disciplinary HealthTech
Aims to help solve one of the biggest challenges facing mankind: brain disorders.
#X-Disciplinary HealthTech
Super-resolution microscopic imaging platform from the Nobel Prize winner’s laboratory.
#X-Disciplinary HealthTech
Advance personalized health management through precision measurements and technology innovation, to become the guardian of human well-being.
#X-Disciplinary HealthTech
A revolutionary new biosensor platform that supports non-invasive continuous blood chemistry monitoring, including O2, Glucose, PH, lactate etc.
#X-Disciplinary HealthTech
The world leader in the next generation of semiconductor ultrasound technology. Its MEMS-based CMUT technology achieves a higher resolution while significantly reducing the cost.
#X-Disciplinary HealthTech
Disruptive digital Elisa protein-detection platform with ultra-high sensitivity, throughput and dynamic range.
#X-Disciplinary HealthTech
The first AI solutions, FDA cleared for medical imaging enhancement Faster, Safer, Smarter.
#X-Disciplinary HealthTech
A platform company aiming to prevent blindness due to Glaucoma and address the biggest challenges in Glaucoma management.
#X-Disciplinary HealthTech